According to a new market research report “Epigenetics Market by Product (Kit, Enzymes, Reagent, NGS, Mass Spectrometer, PCR, Bioinformatics), Application (Oncology, Cardiology, Immunology), Technology (DNA Methylation, Histone Modification), End User (Academic, CRO) – Global Forecast to 2022”, published by MarketsandMarkets™, the market is projected to reach USD 1,605.7 million by 2022 from an estimated USD 854.0 million in 2017, at a CAGR of 13.5% during the forecast period.
Don’t miss out on business opportunities in Epigenetics Market. Speak to our analyst and gain crucial industry insights that will help your business grow:
The key factors that are driving the growth of this market include The decreasing sequencing costs and time, increase in research activities to identify and develop inhibitors/drugs for various diseases, funding for epigenetics research, and rising prevalence of cancer.
Growing applications in Personalized Medicine and Targeted Therapy in Oncology is a growth opportunity for the Epigenetics market
According to a press release published by the Tufts Center for the Study of Drug Development in May 2015, biopharmaceutical companies have nearly doubled their R&D investments in personalized medicine over the last five years, and these investments are further expected to increase by 33% over the next five years. This will further drive the use of epigenetics tools. A 2016 study performed to analyze the epigenetic modification of chronic lymphocytic leukemia (CLL) in the patient population fueled interest in prognostic biomarkers and personalized therapies. This study was performed by CeMM Research Center for Molecular Medicine of the Austrian Academy of Science (Austria) in collaboration with the University of Southampton and the Royal Bournemouth Hospital under the European BLUEPRINT project and the International Human Epigenome Consortium. The expanding application of epigenetics in personalized medicine and targeted therapies, therefore, offers significant opportunities for market growth.
Browse and in-depth TOC on “Epigenetics Market”
191 – Tables
37 – Figures
230 – Pages
View more detailed TOC @
Among the Application Segments, Oncology Dominated the Global Epigenetics Market in 2016
Based on application, the oncology segment accounted for the largest share of the Epigenetics Market in 2016. The large share of this segment can be attributed to the rising prevalence of cancer and the increasing number of research-related activities.
DNA Methylation Segment Dominated the Epigenetics Market, by Technology in 2016
On the basis of technology, the Epigenetics Market is segmented into DNA methylation, histone modifications, and other technologies (includes non-coding RNA and chromatin remodeling). The DNA methylation segment accounted for the largest share of the Global Epigenetics Market in 2016. The large share of this segment is attributed to the increasing incidence of cancer and the ability of this technique to study different types of cancer with quality outcomes.
North America Dominated the Global Epigenetics Market in 2016
North America accounted for the largest share of the Epigenetics Market in 2016, followed by Europe. Increase in epigenetics research activities, favorable government funding initiatives, high R&D expenditure, rising incidence of various diseases, and the presence of key players in the region are the key factors driving the growth of the Epigenetics Market in North America.
Request for Free Sample Report @ https://www.marketsandmarkets.com/requestsample.asp?id=896
The Potential Non-Invasive Prenatal Testing(NIPT) Market is expected to reach more than USD 4 Billion across the 15 major markets(15MM) by the year end of 2021.
More Information @ http://www.dpiresearch.com/page_info.php?P_ID=50
Long–term Growth Projection:
More than 2.5 Million tests will be conducted by the 11 major NIPT test by the year end of 2021.
Non-Invasive Prenatal Testing (NIPT) market size was valued at nearly USD 1 Billion in 2016 and market is expected to grow at the CAGR of XX% during 2017-2021.
Market growth can be attributed to factors such as high incidence rate of babies born with Down syndrome, no risk of miscarriage with NIPT and shifting trend towards child bearing at advanced maternal age (35 years or older). With increased patient access to NIPT test, the NIPT test market is anticipated to have a positive outlook in the coming years. High test cost, strict regulatory requirements and ethical hurdles is restraining the growth of NIPT test market.
NIPT Test Market: Test–wise Outlook
Natera Panorama test will lead the NIPT test market with the market share of more than 25% by the year end of 2021.MaterniT21 Plus and Bambini test have shown its potential to become 2nd and 3rd popular NIPT test. Harmony test is the fourth leading test in the NIPT test market. NIFTY and Verifi test hold the fifth and sixth highest share of the NIPT test market. Other emerging tests such as Prena, IONA, VisibiliT, Veracity and informaseq NIPT test which is likely to affect the market share during the forecast period.
NIPT Test Market: Country–wise Outlook:
United States is the most attractive market with market share of more than 50% in 2016. China will be the second largest market for NIPT test which is expected to grow at a CAGR of XX% by 2021. United Kingdom is expected to be third largest NIPT test market being followed by Germany by the end of the forecasted period.
This is the 3rd edition report on NIPT Test Market by DPI Research.The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, country wise actual and potential market, NIPT test analysis with volume and market revenue and competitive landscape. The report also covers market growth drivers, challenges, current and upcoming trends of the NIPT test market
GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET SEGMENTATION
Global Non-Invasive Prenatal Testing (NIPT) Market – By Test Type
1. MaterniT21 PLUS
11. IONA Test
Global Non-Invasive Prenatal Testing (NIPT) Market – By Country
1. United States
2. United Kingdom
11. New Zealand